Efficacy and Safety of Oral PCSK9 Inhibitors: Insights from a Meta-analysis of RCTS
European Journal of Preventive Cardiology
Current PCSK9 therapies are injectable, which may limit adherence and access. This meta-analysis pooled five randomised trials of three oral PCSK9 inhibitors in 3,295 patients with hypercholesterolaemia on background lipid-lowering therapy.
Over 8–24 weeks, oral PCSK9 inhibition reduced LDL-C by 59% versus placebo, with substantial reductions in apoB, non-HDL-C, and Lp(a), with no serious adverse events. These findings suggest a convenient oral option could expand intensive lipid lowering – although longer outcomes trials are still needed before practice changes.
